Saniona is a Danish-based pharmaceutical company which has recently issued a press release about some exciting news for HO sufferers: the results from their phase 2 study are promising! I have recently had the pleasure to interview Rami Levin, the CEO of Saniona and he and I spoke about the promising and exciting new developments with their new drug for hypothalamic obesity, Tesomet.
If and when the FDA approves the next phase of study, it will be a multi-site study taking place in the United States.
Please click here for the podcast interview of Rami Levin.
For Saniona's Power Point presentation on Tesomet's phase 2 trial for HO, please click here.
